A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

Key facts

Sponsor

Eupraxia Pharmaceuticals Inc.

Principal Investigator

Mark Kowalski, MD PhD

Eupraxia Pharmaceuticals

Intervention

EP-104GI(drug)

Enrollment

117 enrolled

Eligibility

18-75 years · All sexes

Timeline

2023 – 2026

Study locations (23)

• Campbelltown Private Hospital, Sydney, New South Wales, Australia
• Mater Hospital Brisbane, Brisbane, Queensland, Australia
• Princess Alexandra Hospital, Brisbane, Queensland, Australia
• Coastal Digestive Health, Maroochydore, Queensland, Australia
• Royal Adelaide Hospital, Adelaide, South Australia, Australia
• Eastern Health Box Hill, Box Hill, Victoria, Australia
• Northern Hospital Epping, Epping, Victoria, Australia
• The Alfred Hospital, Melbourne, Victoria, Australia
• Royal Melbourne Hospital, Parkville, Victoria, Australia
• University of Calgary, Calgary, Alberta, Canada
• UoA - South Edmonton Gastroenterology Research Clinic, Edmonton, Alberta, Canada
• G.I. Research Institute, Vancouver, British Columbia, Canada
• McGill University Health Center, Montreal, Quebec, Canada
• Amsterdam UMC, Amsterdam, Netherlands
• Erasmus University Medical Center, Holland, Netherlands
• +8 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary eosinophilic gastrointestinal disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06851559
  A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
  Phathom Pharmaceuticals, Inc.
• RECRUITINGNANCT06817213
  Patient-Centered Decision Support for Eosinophilic Esophagitis
  University of Michigan
• RECRUITINGNCT06695897
  A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
  Sanofi
• ACTIVE NOT RECRUITINGPHASE4NCT06352073
  Dupilumab for Eosinophilic Esophagitis With Severe Strictures
  University of North Carolina, Chapel Hill
• RECRUITINGNANCT06381219
  Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot Trial
  Universitaire Ziekenhuizen KU Leuven
• RECRUITINGNCT06991881
  Eosinophilic Esophagitis: Towards Improved Management
  Oslo University Hospital
• RECRUITINGNANCT06501274
  Capsule Sponge Study in Eosinophilic Oesophagitis
  East and North Hertfordshire NHS Trust
• RECRUITINGNANCT05730933
  An Intervention Study to Improve Therapeutic Compliance in Adult Patients With Eosinophilic Esophagitis.
  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

See all trials for Primary eosinophilic gastrointestinal disease →